Phase IIb data released by Abbott Laboratories last week provide the most compelling argument to date that all-oral HCV cocktails do not require a nucleotide-based NS5B inhibitor.

An abstract released ahead of the American Association for the Study of Liver Diseases (AASLD) meeting showed the pharma's five-drug nuc-free cocktail produced one of the highest SVR rates seen thus far in an interferon-free all-oral cocktail, and the highest in patients who were null responders to IFN-based therapy.